Gateway Advisory’s 9 Meters Biopharma NMTR Stock Holding History

Gateway Advisory’s Portfolio NMTR Stock Details NMTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-500	Closed	-$2K	–	88
2022 Q3	$2K	Hold	500	–	–	﹤0.01%	77
2022 Q2	$3K	Hold	500	–	–	﹤0.01%	64
2022 Q1	$6K	Hold	500	–	–	﹤0.01%	97
2021 Q4	$10K	Hold	500	–	–	﹤0.01%	103
2021 Q3	$13K	Hold	500	–	–	﹤0.01%	117
2021 Q2	$11K	Buy	+500	New	+$12.3K	﹤0.01%	104

Other funds holding NMTR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

ODFS

O'Donnell Financial Services San Rafael, California $290M AUM 15.6% 1-Year Est. Return

Gateway Advisory's NMTR Position: Q4 2022 in Review

Gateway Advisory sold out of 9 Meters Biopharma (NMTR) in Q4 2022, closing a stake of 500 shares — an estimated $2K sold.

Gateway Advisory first reported a position in NMTR in Q2 2021 and held it in 6 quarters. The position peaked at $13K in Q3 2021. 42 funds tracked by Wall St. Rank hold NMTR as of Q4 2022.

Gateway Advisory reported no remaining 9 Meters Biopharma position as of Q4 2022 after selling out during the quarter.
Gateway Advisory sold 500 9 Meters Biopharma shares in Q4 2022, an estimated $2K.
Gateway Advisory first reported a position in 9 Meters Biopharma in Q2 2021 and held it in 6 quarters.
Gateway Advisory's 9 Meters Biopharma position peaked at $13K in Q3 2021.
42 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q4 2022.

Based on Gateway Advisory's 13F filing for Q4 2022, filed 14 Feb 2023.